⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 25, 2026EJNMMI ResearchOpen Access

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE

Fei Liu Hongxing Yang Jianping Zhang Jindian Li Ying Qiao Jie Chen Shaoli Song

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates the relationship between absorbed doses and SUV from SPECT/CT imaging in patients treated for neuroendocrine tumors.
Compared treatment outcomes of Lutetium-177 and Octreotide in patients with GEP-NETs.
Utilized SPECT/CT imaging to measure absorbed dose and SUV.
Analyzed dose-response relationships based on imaging results.
Found significant correlations between absorbed dose and SUV.
Indicated favorable responses in patients treated with Lutetium-177.
Demonstrated improved treatment efficacy compared to Octreotide.

Implication

Study compares absorbed dose and SUV results in neuroendocrine tumors indicating treatment efficacy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69a134fbed1d949a99abe6d8 https://doi.org/10.1186/s13550-026-01402-2

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine2024 · 60 citations
2Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE2024 · 40 citations
3Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with <sup>177</sup> Lu DOTA-TATE and <sup>177</sup> Lu DOTA-NOCOriginal Research · 2007 · 177 citations
4Quantitative SPECT/CT Metrics in Early Prediction of [<sup>177</sup>Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients2024 · 9 citations
5Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours2024 · 18 citations

More related papers

Safety and time to response of [<sup>177</sup>Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.2024
Pharmacokinetics and Dosimetry of <sup>177</sup> Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial2026
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors2018

More from EJNMMI Research

Preclinical evaluation of PD-L1 targeted radiotherapy in a xenograft mouse model of triple-negative breast cancerMon,
Current practices and access to cardiac bone scintigraphy for diagnosing transthyretin cardiac amyloidosis: results of a large national surveyMon,